Artemis Medicare Services Ltd is Rated Sell

9 hours ago
share
Share Via
Artemis Medicare Services Ltd is rated 'Sell' by MarketsMojo, with this rating last updated on 02 March 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Artemis Medicare Services Ltd is Rated Sell

Current Rating Overview

MarketsMOJO currently assigns Artemis Medicare Services Ltd a 'Sell' rating, reflecting a cautious stance on the stock. This rating was revised on 02 March 2026, when the company’s Mojo Score declined by 11 points from 54 to 43, signalling a shift in the overall assessment. The 'Sell' rating indicates that, based on a comprehensive evaluation of various parameters, the stock is expected to underperform relative to the broader market and may carry elevated risks for investors at this time.

Here’s How Artemis Medicare Services Ltd Looks Today

As of 05 April 2026, Artemis Medicare Services Ltd is classified as a small-cap company operating within the hospital sector. The latest data shows a mixed performance across key evaluation criteria, which collectively inform the current rating.

Quality Assessment

The company’s quality grade is considered average. This suggests that while Artemis Medicare Services Ltd maintains a stable operational foundation, it does not exhibit the robust competitive advantages or superior profitability metrics that typically characterise higher-quality stocks. Investors should note that average quality may imply moderate business risks and limited resilience against sector headwinds.

Valuation Perspective

From a valuation standpoint, the stock appears attractive. This indicates that, relative to its earnings, assets, and sector peers, Artemis Medicare Services Ltd is trading at a price level that could offer value to investors seeking potential bargains. However, valuation alone does not guarantee positive returns, especially when other factors such as financial trends and technical indicators are less favourable.

Financial Trend Analysis

Financially, the company demonstrates a positive trend. This is a favourable sign, reflecting improvements or stability in key financial metrics such as revenue growth, profitability, or cash flow generation. Such trends can provide a foundation for future growth, although they must be weighed alongside other considerations before making investment decisions.

Technical Outlook

Technically, the stock is rated bearish. This suggests that recent price movements and chart patterns indicate downward momentum, which may deter short-term investors or traders. The bearish technical grade often reflects market sentiment and can influence liquidity and volatility in the stock.

Stock Performance and Market Context

As of 05 April 2026, Artemis Medicare Services Ltd has experienced notable price fluctuations. The stock recorded a 1-day gain of 1.78%, but over longer periods, it has underperformed. Specifically, the 1-month return stands at -2.51%, the 3-month return at -19.20%, and the year-to-date return at -16.85%. Over the past year, the stock has declined by 15.90%, significantly underperforming the BSE500 index, which itself posted a negative return of -1.85% during the same period. This underperformance highlights challenges the company faces relative to the broader market.

Promoter Shareholding and Risk Factors

One critical risk factor for investors is the high level of pledged promoter shares, currently at 44.53%. High promoter pledging can exert additional downward pressure on the stock price, especially in falling markets, as it may lead to forced selling or increased volatility. This factor contributes to the cautious stance reflected in the 'Sell' rating.

Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.

  • - New Reliable Performer
  • - Steady quarterly gains
  • - Fertilizers consistency

Discover the Steady Winner →

What the 'Sell' Rating Means for Investors

The 'Sell' rating from MarketsMOJO suggests that investors should exercise caution with Artemis Medicare Services Ltd at this juncture. While the stock’s valuation appears attractive and financial trends are positive, the average quality, bearish technical outlook, and significant promoter share pledging present risks that may outweigh potential rewards. Investors might consider this rating as a signal to limit exposure or seek alternative opportunities with stronger fundamentals and technical momentum.

Sector and Market Considerations

Operating in the hospital sector, Artemis Medicare Services Ltd faces sector-specific challenges such as regulatory changes, competitive pressures, and evolving healthcare demands. The company’s current performance and rating should be viewed within this broader context, recognising that sector dynamics can materially impact future prospects.

Summary

In summary, Artemis Medicare Services Ltd’s current 'Sell' rating reflects a balanced assessment of its strengths and vulnerabilities as of 05 April 2026. Investors are advised to carefully analyse the company’s financial health, market position, and risk factors before making investment decisions. The rating underscores the importance of a cautious approach given the stock’s recent underperformance and technical signals.

Looking Ahead

For investors monitoring Artemis Medicare Services Ltd, it will be important to watch for improvements in quality metrics, reductions in promoter share pledging, and a reversal in technical trends. Any positive developments in these areas could warrant a reassessment of the stock’s outlook and rating in the future.

Final Thoughts

MarketsMOJO’s comprehensive evaluation provides a data-driven foundation for understanding Artemis Medicare Services Ltd’s current market standing. The 'Sell' rating is a reflection of the company’s present challenges and risks, balanced against pockets of value and financial positivity. Investors should integrate this insight with their own research and risk tolerance when considering the stock.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News